Chemical Compound Review:
Glufast 4-(1,3,3a,4,5,6,7,7a- octahydroisoindol-2...
Synonyms:
AC1MILSA, AC1NUHLY, CHEMBL471498, SureCN676865, Kad-1229, ...
- Characterization of the action of S 21403 (mitiglinide) on insulin secretion and biosynthesis in normal and diabetic beta-cells. Kaiser, N., Nesher, R., Oprescu, A., Efendic, S., Cerasi, E. Br. J. Pharmacol. (2005)
- Effects of mitiglinide and sulfonylureas in isolated canine coronary arteries and perfused rat hearts. Maruyama, I., Tomiyama, Y., Maruyama, K., Ojima, K., Kobayashi, K., Kobayashi, M., Yamazaki, Y., Kojima, M., Shibata, N. Eur. J. Pharmacol. (2006)
- Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus. Yoshihara, T., Kumashiro, N., Kanazawa, Y., Mita, T., Sakurai, Y., Kawai, J., Abe, M., Motojima, K., Hara, K., Yamazaki, Y., Kanazawa, A., Miwa, S., Sato, F., Kanno, R., Shimizu, T., Sakai, K., Uchino, H., Watada, H., Tanaka, Y., Kawamori, R., Hirose, T. Endocr. J. (2006)
- Determination of mitiglinide in rat plasma by high-performance liquid chromatography with UV detection. Lushan, Y., Su, Z. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2006)
- Study of the insulinotropic effect of the novel antihyperglycemic agent KAD-1229 using HIT T15 cells, a hamster's insulinoma cell line. Ichikawa, K., Yamato, T., Tsuji, A., Ojima, K., Kusama, H., Kojima, M. Arzneimittel-Forschung. (2002)
- Imaging docking and fusion of insulin granules induced by antidiabetes agents: sulfonylurea and glinide drugs preferentially mediate the fusion of newcomer, but not previously docked, insulin granules. Nagamatsu, S., Ohara-Imaizumi, M., Nakamichi, Y., Kikuta, T., Nishiwaki, C. Diabetes (2006)
- Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Assaloni, R., Da Ros, R., Quagliaro, L., Piconi, L., Maier, A., Zuodar, G., Motz, E., Ceriello, A. Diabetologia (2005)
- Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel. Reimann, F., Proks, P., Ashcroft, F.M. Br. J. Pharmacol. (2001)
- The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Sunaga, Y., Gonoi, T., Shibasaki, T., Ichikawa, K., Kusama, H., Yano, H., Seino, S. Eur. J. Pharmacol. (2001)
- Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats. Mori, Y., Ojima, K., Fuujimori, Y., Fujimori, Y., Aoyagi, I., Kusama, H., Yamazaki, Y., Kojima, M., Kojima, S., Shibata, N., Itoh, Y., Tajima, N. Endocrine (2006)
- Inhibition of heterologously expressed cystic fibrosis transmembrane conductance regulator Cl- channels by non-sulphonylurea hypoglycaemic agents. Cai, Z., Lansdell, K.A., Sheppard, D.N. Br. J. Pharmacol. (1999)
- Long-term Effect of Combination Therapy with Mitiglinide and Once Daily Insulin Glargine in Patients who were Successfully Switched from Intensive Insulin Therapy in Short-term Study. Kumashiro, N., Yoshihara, T., Kanazawa, Y., Shimizu, T., Watada, H., Tanaka, Y., Fujitani, Y., Kawamori, R., Hirose, T. Endocr. J. (2007)
- Recent developments and emerging therapies for type 2 diabetes mellitus. Evans, A.J., Krentz, A.J. Drugs in R&D. (1999)